Evidence map›Paper›PMID 40330897›Full record

ArticleThe application of clinical genetics2025

The Frequency of

Yves Donald Kagambèga, Abdoul Karim Ouattara, Teega-Wendé Clarisse Ouédraogo, Lassina Traoré, Nobila Valentin Yaméogo, Jacques Simpore

Abstract read
In one paragraph

Article in The application of clinical genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yves Donald Kagambèga *Biological Sciences, Université Norbert Zongo/ Centre Universitaire de Manga, Koudougou, Burkina Faso.ORCID 0009-0006-3673-506X
Abdoul Karim Ouattara *Biological Sciences, Université Norbert Zongo/ Centre Universitaire de Manga, Koudougou, Burkina Faso.
Teega-Wendé Clarisse OuédraogoBiochimie Microbiologie, Laboratoire de Biologie Moléculaire et de Génétique (LABIOGENE) - Université Joseph KI-ZERBO, Ouagadougou, Burkina Faso.
Lassina TraoréBiochimie Microbiologie, Laboratoire de Biologie Moléculaire et de Génétique (LABIOGENE) - Université Joseph KI-ZERBO, Ouagadougou, Burkina Faso.
Nobila Valentin YaméogoService de Cardiologie, Centre Hospitalier Universitaire Yalgado Ouédraogo, Ouagadougou, Burkina Faso.
Jacques SimporeBiological Sciences, Université Norbert Zongo/ Centre Universitaire de Manga, Koudougou, Burkina Faso.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The hepatic cytochrome P450 2C19 (CYP2C19) superfamily plays a crucial role in converting clopidogrel into its active form. Polymorphisms in Patients and Methods: This cross-sectional study recruited a total of seventy-three (73) patients from the Cardiology Department of the Centre Hospitalier Universitaire Yalgado Ouédraogo (CHU-YO) between January and June 2023. DNA was extracted from blood samples for Results: Genetic analysis revealed frequencies of 65.8% for the wild-type CYP2C19*1/*1, 28.8% for the heterozygous CYP2C19*1/*2, and 2.7% for the homozygous variant CYP2C19*2/*2. The distribution of the genotypic frequencies was consistent with Hardy-Weinberg equilibrium (p> 0.05). The overall frequency of the Conclusion: This study provides valuable insights into the frequency of the CYP2C19*2 polymorphism among cardiovascular patients in Burkina Faso, contributing to the limited data available on

Indexed as

Burkina Fasocardiovascular diseasesclopidogrelCYP2C19PCR-RFLPpolymorphism

Identifiers

PMID40330897
PMCPMC12052008

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.